PMID- 31359514
OWN - NLM
STAT- MEDLINE
DCOM- 20191226
LR  - 20200108
IS  - 1099-1573 (Electronic)
IS  - 0951-418X (Linking)
VI  - 33
IP  - 10
DP  - 2019 Oct
TI  - Natural products with SGLT2 inhibitory activity: Possibilities of application for 
      the treatment of diabetes.
PG  - 2518-2530
LID - 10.1002/ptr.6421 [doi]
AB  - Diabetes mellitus currently affects as many as 400 million people worldwide, 
      creating a heavy economic burden and stretching health care resources. A 
      dysfunction of glucose homeostasis underlies the disease. Despite advances in the 
      treatment of diabetes, many patients still suffer from complications and side 
      effects; hence, development of more effective treatments for diabetes is still 
      desirable. SGLT2 is the principle cotransporter involved in glucose reabsorption 
      in the kidney. SGLT2 inhibition reduces glucose reabsorption by the kidney and 
      ameliorates plasma glucose concentration. The interest in natural products that 
      can be used for the inhibition of SGLT2 is growing. The flavonoid phlorizin, 
      which can be isolated from the bark of apple trees, has been used as lead 
      structure due to its inhibitory activity of SGLT1 and SGLT2. Some 
      phlorizin-derived synthetic compounds, including canagliflozin, dapagliflozin, 
      empagliflozin, ipragliflozin, and ertugliflozin, are approved by the food and 
      drug administration to treat type 2 diabetes mellitus (T2DM), whereas others are 
      under clinical trials investigation. In addition, other natural product-derived 
      compounds have been investigated for their ability to improve blood glucose 
      control. The present review summarizes the natural products with SGLT2 inhibitory 
      activity, and the synthetic compounds obtained from them, and discusses their 
      application for the treatment of diabetes.
CI  - (c)2019 John Wiley & Sons, Ltd.
FAU - Moradi-Marjaneh, Reyhaneh
AU  - Moradi-Marjaneh R
AD  - Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.
FAU - Paseban, Maryam
AU  - Paseban M
AD  - Department of Physiology, School of Medicine, Mashhad University of Medical 
      Sciences, Mashhad, Iran.
FAU - Sahebkar, Amirhossein
AU  - Sahebkar A
AUID- ORCID: 0000-0002-8656-1444
AD  - Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad 
      University of Medical Sciences, Mashhad, Iran.
AD  - Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, 
      Mashhad, Iran.
AD  - School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190729
PL  - England
TA  - Phytother Res
JT  - Phytotherapy research : PTR
JID - 8904486
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Biological Products)
RN  - 0 (Glucosides)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Thiophenes)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 3N2N8OOR7X (ipragliflozin)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/therapeutic use
MH  - Biological Products/*therapeutic use
MH  - Canagliflozin/therapeutic use
MH  - Diabetes Mellitus/*drug therapy
MH  - Glucosides/therapeutic use
MH  - Humans
MH  - Sodium-Glucose Transporter 2 Inhibitors/pharmacology/*therapeutic use
MH  - Thiophenes/therapeutic use
OTO - NOTNLM
OT  - SGLT2
OT  - diabetes
OT  - phytochemical
EDAT- 2019/07/31 06:00
MHDA- 2019/12/27 06:00
CRDT- 2019/07/31 06:00
PHST- 2019/02/12 00:00 [received]
PHST- 2019/05/15 00:00 [revised]
PHST- 2019/05/26 00:00 [accepted]
PHST- 2019/07/31 06:00 [pubmed]
PHST- 2019/12/27 06:00 [medline]
PHST- 2019/07/31 06:00 [entrez]
AID - 10.1002/ptr.6421 [doi]
PST - ppublish
SO  - Phytother Res. 2019 Oct;33(10):2518-2530. doi: 10.1002/ptr.6421. Epub 2019 Jul 
      29.